Henry Schein to Serve as Exclusive Distributor of Curodont to Dental Service Organizations
September 17 2024 - 6:30AM
Business Wire
Henry Schein, Inc. (Nasdaq: HSIC) announced that it has reached
an agreement with the Swiss company vVARDIS to serve as the
exclusive distributor of their drill-free Curodont™ Repair Fluoride
Plus product to larger dental service organizations (DSOs) in the
U.S.
Developed by vVARDIS, Curodont™ Repair Fluoride Plus is a
proprietary solution that addresses early-stage tooth decay by
aiding in the preventive treatment of cavity progression, with an
innovative simple, quick, and drill-free application. It is widely
recognized that poor oral health can impact overall health, and
untreated decay can become life-threatening. Nearly 80% of all
patients have signs of early decay and the majority will leave the
dental office without treatment, risking more serious disease.
Curodont™ Repair Fluoride Plus will empower dental practices to
address this untapped opportunity, expanding patient care with a
non-invasive approach.
“We believe that Curodont advances clinical care by treating
early decay before it worsens,” said Stanley M. Bergman, Chairman
of the Board and Chief Executive Officer of Henry Schein, the
world’s largest provider of health care solutions to office-based
dental and medical practitioners. “With this treatment, the dental
team can treat early-stage caries non-invasively and on the same
day instead of sending patients home untreated. Henry Schein is
pleased to bring products to market that improve clinical outcomes,
including Curodont™ Repair Fluoride Plus, while helping practices
operate more efficiently and effectively by advancing oral health
and overall health for the ultimate benefit of the patient.”
The partnership between Henry Schein and vVARDIS builds on other
innovations that support early treatment of oral disease. In late
2022, Henry Schein One introduced Dentrix® Detect AI, powered and
manufactured by VideaHealth. Dentrix® Detect AI is an AI-enabled
X-ray analysis tool that provides real-time clinical decision
support and can detect incipient carious lesions more accurately
than the naked eye, expanding the patient population that could
benefit from the use of Curodont™ Repair Fluoride Plus. Dental
professionals who use Dentrix® Detect AI and Curodont™ Repair
Fluoride Plus in concert may help to more effectively treat early
carious lesions before greater disease progression occurs.
Henry Schein currently is the market leader in selling Curodont™
Repair Fluoride Plus, with its novel approach, to general
practitioners and DSOs. With this agreement, Henry Schein will have
the exclusive rights to distribute Curodont™ Repair Fluoride Plus
to larger DSOs, a market segment driving significant growth. The
Company will continue to distribute Curodont products to other
segments of the market and in other markets outside of North
America, as product registrations are obtained. The terms of the
agreement were not disclosed.
“We are excited to strengthen our partnership with Henry Schein,
a recognized leader in driving technological innovation in
dentistry,” said Drs. Haley and Goly Abivardi, DMDs, visionary
Founders and Co-CEOs of vVARDIS. “Henry Schein’s global reach makes
for an ideal partner as we share a common goal: advancing oral
health by providing access to innovative, non-invasive solutions.
Through this partnership, almost every patient can now benefit from
Curodont. As both dentists and entrepreneurs, we are thrilled to
finally have and offer a novel approach to treating early decay.
Dental professionals have been waiting for decades for a drill-free
treatment that addresses the sub-clinical signs of caries
immediately, without sending patients home untreated and
compromising their overall health. With its seamless integration
into existing workflows, we believe that Curodont has the potential
to rapidly become the new standard of care for the treatment of
early caries, broadening the scope of services offered and
empowering dentists and hygienists to lead the way in the
management of early caries, ultimately enhancing patient care.”
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for
health care professionals powered by a network of people and
technology. With more than 25,000 Team Schein Members worldwide,
the Company's network of trusted advisors provides more than 1
million customers globally with more than 300 valued solutions that
help improve operational success and clinical outcomes. Our
Business, Clinical, Technology, and Supply Chain solutions help
office-based dental and medical practitioners work more efficiently
so they can provide quality care more effectively. These solutions
also support dental laboratories, government and institutional
health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 300,000 branded
products and Henry Schein corporate brand products in our
distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index,
Henry Schein is headquartered in Melville, N.Y., and has operations
or affiliates in 33 countries and territories. The Company's sales
reached $12.3 billion in 2023, and have grown at a compound annual
rate of approximately 11.5 percent since Henry Schein became a
public company in 1995.
For more information, visit Henry Schein at www.henryschein.com,
Facebook.com/HenrySchein, Instagram.com/HenrySchein, and
@HenrySchein on X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240916637611/en/
Ann Marie Gothard Vice President, Global Corporate Media
Relations annmarie.gothard@henryschein.com (631) 390-8169
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Dec 2023 to Dec 2024